FDA panel backs peptides over its own scientists

Six of seven compounds clear a reconstituted committee, as questions mount over evidence, access and who benefits. A divided advisory panel to the US Food and Drug Administration voted this week to recommend six of seven reviewed peptides for addition to the list of substances that licensed pharmacies may legally compound [1]. The Pharmacy Compounding […] The post FDA panel backs peptides over its own scientists appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.